Cargando…

SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants

PURPOSE: Patients with antibody deficiencies often receive maintenance treatment with donor plasma-derived immunoglobulin (Ig) preparations to decrease the incidence and severity of infections. We have previously shown that IgG antibodies to the original SARS-CoV-2 strain were not consistently prese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindahl, Hannes, Chen, Puran, Åberg, Mikael, Ljunggren, Hans-Gustaf, Buggert, Marcus, Aleman, Soo, Smith, C. I. Edvard, Bergman, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102687/ https://www.ncbi.nlm.nih.gov/pubmed/37058198 http://dx.doi.org/10.1007/s10875-023-01486-8

Ejemplares similares

Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant
por: Lindahl, Hannes, et al.
Publicado: (2022)

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
por: Gao, Yu, et al.
Publicado: (2022)

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID
por: Chen, Puran, et al.
Publicado: (2023)

Elevated CD21(low) B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency
por: Bergman, Peter, et al.
Publicado: (2022)

T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial
por: Blixt, Lisa, et al.
Publicado: (2022)

MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine
por: Boulouis, Caroline, et al.
Publicado: (2022)

Persistence of salivary antibody responses after COVID-19 vaccination is associated with oral microbiome variation in both healthy and people living with HIV
por: Ghorbani, Mahin, et al.
Publicado: (2023)

Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia
por: Andersson, Maria, et al.
Publicado: (2023)

Functional SARS-CoV-2 cross-reactive CD4(+) T cells established in early childhood decline with age
por: Humbert, Marion, et al.
Publicado: (2023)

COVID-19 in a patient with Good's syndrome and in 13 patients with common variable immunodeficiency
por: Lindahl, Hannes, et al.
Publicado: (2021)

Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy
por: Lindahl, Hannes, et al.
Publicado: (2023)

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
por: Bergman, Peter, et al.
Publicado: (2021)

Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox
por: Adamo, Sarah, et al.
Publicado: (2023)

Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID‐19 in chronic lymphocytic leukaemia?
por: Smith, Carl Inge Edvard, et al.
Publicado: (2022)

Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals
por: Healy, Katie, et al.
Publicado: (2022)

SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation
por: Sandberg, John Tyler, et al.
Publicado: (2021)

Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2
por: Ahn, Terrie S., et al.
Publicado: (2021)

Unique transcriptional and protein-expression signature in human lung tissue-resident NK cells
por: Marquardt, Nicole, et al.
Publicado: (2019)

Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations
por: Hooper, John A.
Publicado: (2008)

NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
por: Cuapio, Angelica, et al.
Publicado: (2022)

Hierarchical modelling of immunoglobulin coated bacteria in dogs with chronic enteropathy shows reduction in coating with disease remission but marked inter-individual and treatment-response variability
por: Martínez-López, Lina María, et al.
Publicado: (2021)

Marked improvement of Churg–Strauss syndrome neuropathy by intravenous immunoglobulin and cyclophosphamide
por: Umeda, Akira, et al.
Publicado: (2014)

Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
por: Gao, Yu, et al.
Publicado: (2022)

Expansions of adaptive-like NK cells with a tissue-resident phenotype in human lung and blood
por: Brownlie, Demi, et al.
Publicado: (2021)

Paths taken towards NK cell–mediated immunotherapy of human cancer—a personal reflection
por: Ljunggren, Hans‐Gustaf
Publicado: (2020)

Mucosal immunoglobulins at respiratory surfaces mark an ancient association that predates the emergence of tetrapods
por: Xu, Zhen, et al.
Publicado: (2016)

Comparison of Lung-Homing Receptor Expression and Activation Profiles on NK Cell and T Cell Subsets in COVID-19 and Influenza
por: Brownlie, Demi, et al.
Publicado: (2022)

A case of myelodysplastic syndrome with marked eosinophilia showing favorable prognosis
por: Kim, Min Ji, et al.
Publicado: (2013)

Cross reactive T cells hold up against Omicron
por: Flemming, Alexandra
Publicado: (2022)

Guardians of the oral barriers
por: Buggert, Marcus
Publicado: (2023)

Perturbed CD8(+) T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals
por: Tauriainen, Johanna, et al.
Publicado: (2017)

MAIT cell activation and dynamics associated with COVID-19 disease severity
por: Parrot, Tiphaine, et al.
Publicado: (2020)

Evaluation of Commercially Available Anti–Dengue Virus Immunoglobulin M Tests
por: Hunsperger, Elizabeth A., et al.
Publicado: (2009)

Evaluation of Commercially Available Chikungunya Virus Immunoglobulin M Detection Assays
por: Johnson, Barbara W., et al.
Publicado: (2016)

Evaluation of three commercially-available chikungunya virus immunoglobulin G immunoassays
por: De Salazar, Pablo M, et al.
Publicado: (2017)

Comparative Neutralization Activity of Commercial Rabies Immunoglobulin against Diverse Lyssaviruses
por: Coertse, Jessica, et al.
Publicado: (2023)

Activated Natural Killer Cells Hit Neurogenesis in the Aging Brain
por: Cuapio, Angelica, et al.
Publicado: (2021)

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
por: Nutalai, Rungtiwa, et al.
Publicado: (2022)

Immunoglobulin G4-related Disease with Marked Eosinophilia: A Case Report and Literature Review
por: Origuchi, Tomoki, et al.
Publicado: (2022)

Serum immunoglobulin E and immunoglobulin G reactivity to Agaricus bisporus proteins in mushroom cultivation workers
por: Khakzad, Z, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_489bkg909ukiqekirtmle5mfg9